Abstract:Circulation Research, Ahead of Print. BACKGROUND:Hyperproliferation of pulmonary arterial smooth muscle cells (PASMCs) and consequent pulmonary vascular remodeling are the crucial pathological features of pulmonary hypertension (PH). Protein methylation has been shown to be critically involved in PASMC proliferation and PH, but the underlying mechanism remains largely unknown.METHODS:PH animal models were generated by treating mice/rats with chronic hypoxia for 4 weeks. SMYD2-vTg mice (vascular smooth muscle cell-specific suppressor of variegation, enhancer of zeste, trithorax and myeloid Nervy DEAF-1 domain-containing protein 2 transgenic) or wild-type rats and mice treated with LLY-507 were used to investigate the function of SMYD2 (suppressor of variegation, enhancer of zeste, trithorax and myeloid Nervy DEAF-1 domain-containing protein 2) on PH development in vivo. Primary cultured rat PASMCs with SMYD2 knockdown or overexpression were used to explore the effects of SMYD2 on proliferation and to decipher the underlying mechanism.RESULTS:We demonstrated that the expression of the lysine methyltransferase SMYD2 was upregulated in the smooth muscle cells of pulmonary arteries from patients with PH and hypoxia-exposed rats/mice and in the cytoplasm of hypoxia-induced rat PASMCs. More importantly, targeted inhibition of SMYD2 by LLY-507 significantly attenuated hypoxia-induced pulmonary vascular remodeling and PH development in both male and female rats in vivo and reduced rat PASMC hyperproliferation in vitro. In contrast, SMYD2-vTg mice exhibited more severe PH phenotypes and related pathological changes than nontransgenic mice after 4 weeks of chronic hypoxia treatment. Furthermore, SMYD2 overexpression promoted, while SMYD2 knockdown suppressed, the proliferation of rat PASMCs by affecting the cell cycle checkpoint between S and G2 phases. Mechanistically, we revealed that SMYD2 directly interacted with and monomethylated PPARγ (peroxisome proliferator-activated receptor gamma) to inhibit the nuclear translocation and transcriptional activity of PPARγ, which further promoted mitophagy to facilitate PASMC proliferation and PH development. Furthermore, rosiglitazone, a PPARγ agonist, largely abolished the detrimental effects of SMYD2 overexpression on PASMC proliferation and PH.CONCLUSIONS:Our results demonstrated that SMYD2 monomethylates nonhistone PPARγ and inhibits its nuclear translocation and activation to accelerate PASMC proliferation and PH by triggering mitophagy, indicating that targeting SMYD2 or activating PPARγ are potential strategies for the prevention of PH.

SOD2 Ameliorates Pulmonary Hypertension in a Murine Model of Sleep Apnea Via Suppressing Expression of NLRP3 in CD11b+ Cells.

Heterozygous SOD2 Deletion Deteriorated Chronic Intermittent Hypoxia-Induced Lung Inflammation and Vascular Remodeling Through Mtros-Nlrp3 Signaling Pathway

Increased Nitrosoglutathione Reductase Activity in Hypoxic Pulmonary Hypertension in Mice

A Protective Role of SOD1 Overexpression in Central Mediation of Bradycardia Following Chronic Intermittent Hypoxia in Mice.

2‐Methoxyestradiol Attenuates Chronic‐intermittent‐hypoxia‐induced Pulmonary Hypertension Through Regulating Microrna‐223

Redistribution of SOD3 expression due to R213G polymorphism affects pulmonary interstitial macrophage reprogramming in response to hypoxia

Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension.

Extracellular Superoxide Dismutase Regulates Early Vascular Hyaluronan Remodeling in Hypoxic Pulmonary Hypertension

Sulfur Dioxide Upregulates the Inhibited Endogenous Hydrogen Sulfide Pathway in Rats with Pulmonary Hypertension Induced by High Pulmonary Blood Flow

Exacerbated Pulmonary Arterial Hypertension and Right Ventricular Hypertrophy in Animals with Loss of Function of Extracellular Superoxide Dismutase.

Pde5 Inhibition Reduced Blood Pressure and Alleviated Target Organ Damage in Chronic Intermittent Hypoxia

Regulatory mechanism of downregulation of SOD1 expression on cardiomyocyte function

Alteration of Extracellular Superoxide Dismutase in Idiopathic Pulmonary Arterial Hypertension

Phosphodiesterase 4B Activation Exacerbates Pulmonary Hypertension Induced by Intermittent Hypoxia by Regulating Mitochondrial Injury and Camp/pka/p-Creb/pgc-1α Signaling

Lung EC-SOD Overexpression Prevents Hypoxia-Induced Platelet Activation and Lung Platelet Accumulation

Nr1d1 inhibition mitigates intermittent hypoxia-induced pulmonary hypertension via Dusp1-mediated Erk1/2 deactivation and mitochondrial fission attenuation

Inhibition of Mir-4640-5p Alleviates Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Patients by Regulating Nitric Oxide Synthase 1

Endothelial Cell-Derived SO2 Controls Endothelial Cell Inflammation, Smooth Muscle Cell Proliferation, and Collagen Synthesis to Inhibit Hypoxic Pulmonary Vascular Remodelling

SMYD2-Methylated PPARγ Facilitates Hypoxia-Induced Pulmonary Hypertension by Activating Mitophagy

Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

Endothelial Indoleamine 2,3-Dioxygenase Protects Against Development of Pulmonary Hypertension